Literature DB >> 24457356

Abnormal retinal thickening is a common feature among patients with ARSACS-related phenotypes.

Patrick Yu-Wai-Man1, Angela Pyle, Helen Griffin, Mauro Santibanez-Korev, Rita Horvath, Patrick F Chinnery.   

Abstract

Entities:  

Keywords:  Genetics; Optic Nerve

Mesh:

Substances:

Year:  2014        PMID: 24457356      PMCID: PMC3995215          DOI: 10.1136/bjophthalmol-2013-304534

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


× No keyword cloud information.
Autosomal-recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) was first described among French Canadian patients from Québec presenting with a stereotypical triad of early-onset cerebellar ataxia, spastic paraplegia and peripheral neuropathy. Two recurring pathogenic mutations in the SACS gene were subsequently identified in these families in keeping with a mutational founder event in a geographically isolated population.1 However, ARSACS is being increasingly recognised worldwide as an important cause of inherited ataxia.2 Interestingly, non-Québec patients can show strikingly variable features marked by a lack of spasticity, cognitive impairment and a delayed age of onset.2 Given the heterogeneous clinical picture that can be associated with SACS mutations, the identification of ancillary features linked with these genetic defects could prove particularly useful in prioritising the most appropriate lines of investigations when confronted with a suspected case of ARSACS. Although prominent retinal hypermyelination is thought to be a characteristic manifestation of classical ARSACS among Québec patients, this ophthalmological finding has only been described infrequently in patients from Europe, Asia and the Middle East.2 A recent case report has even further argued that retinal ‘hypermyelination’ in ARSACS is a pathologically misleading term that should be abandoned in favour of retinal nerve fibre layer (RNFL) hypertrophy.3 To more accurately define the nature of the retinal findings in ARSACS and its possible practical relevance as a screening tool in routine clinical practice, we carried out a comprehensive neuro-ophthalmological examination of five patients from the North of England with molecularly confirmed ARSACS (table 1).4 5 Topographic analysis of the optic disc was performed with the Spectralis optical coherence tomography (OCT) platform (Heidelberg Engineering, Heidelberg, Germany).
Table 1

Clinical features and retinal nerve fibre layer measurements in patients with pathogenic SACS mutations

PatientAge (years)SexOnset (years)Clinical features SACS mutationsAverage RNFL Thickness
OD (μm)OS (μm)
A48F26Gait ataxia, dysarthria, spastic paraplegia and peripheral neuropathyc.2076delG (p.Thr692ThrfsX713);c.3965_3966delAC (p.Gly1322ValfsX1343)174175
B45M19Gait ataxia, dysarthria, spastic paraplegia and peripheral neuropathy162140
C43MLate-teensGait ataxia, dysarthria, proximal myopathy and peripheral neuropathyc.13048G>T (p.Glu4350X); 0.7Mb deletion (13q12.12)138122
D46MMid-teensGait ataxia, dysarthria, proximal myopathy and peripheral neuropathy152169
E69MLate-teensGait ataxia, spastic paraplegia and peripheral neuropathyc.1580C>G (p.Ser527X); c.6781C>A (p.Leu2261Ile)11186

Patients A and B, and patients C and D, are two pairs of siblings. The molecular genetic characterisation of these four patients with next-generation whole exome sequencing has been previously reported.4 5 All the patients presented with progressive gait ataxia and they were severely disabled, requiring the use of a wheelchair for ambulation. Four patients (A, B, C and D) had significant peripapillary RNFL thickening outside the normal range for healthy controls (mean average thickness=100.3 μm, SD=1.8 μm). No patient had a significant refractive error that could be a confounding variable in the analysis of peripapillary RNFL thickness.

OD, right eye; OS, left eye; RNFL, retinal nerve fibre layer.

Clinical features and retinal nerve fibre layer measurements in patients with pathogenic SACS mutations Patients A and B, and patients C and D, are two pairs of siblings. The molecular genetic characterisation of these four patients with next-generation whole exome sequencing has been previously reported.4 5 All the patients presented with progressive gait ataxia and they were severely disabled, requiring the use of a wheelchair for ambulation. Four patients (A, B, C and D) had significant peripapillary RNFL thickening outside the normal range for healthy controls (mean average thickness=100.3 μm, SD=1.8 μm). No patient had a significant refractive error that could be a confounding variable in the analysis of peripapillary RNFL thickness. OD, right eye; OS, left eye; RNFL, retinal nerve fibre layer. No patient had evidence of retinal hypermyelination. Retinal striations were observed around the optic discs in four patients (A, B, C and D) and OCT measurements showed significant generalised peripapillary RNFL thickening (see online supplementary figures S1–S4). Patient E had no fundus abnormalities, and the peripapillary RNFL thickness was within the normal range for healthy controls (see online supplementary figure S5). Our case series has provided convincing evidence that abnormal retinal thickening is a common, although not universal, feature among patients with ARSACS-related phenotypes secondary to pathogenic SACS mutations. Significant peripapillary RNFL thickening has also been previously reported in eight patients harbouring confirmed pathogenic SACS mutations with different OCT imaging platforms to the one used in our study.6–8 Classical myelinated retinal nerve fibres were not observed, and the current body of evidence, at least among non-Québec patients, suggests that retinal ‘hypermyelination’ has been used inappropriately to describe the striated appearance of a thickened RNFL around the optic discs. The pathophysiological basis for this observation remains to be determined, but it is rather revealing that the sacsin protein localises to mitochondria. In a transgenic knock-out mouse model, depletion of the sacsin protein resulted in disruption of mitochondrial axonal transport and cerebellar neurones with aberrant dendritic morphologies.9 Although speculative, RNFL thickening in ARSACS could therefore be related to axoplasmic stasis within the long axons of the retinal ganglion cells as they converge to form the optic nerve in the anatomically constrained region of the lamina cribosa. The investigation of a large multicentre cohort of patients with ARSACS will be needed to determine whether the degree of RNFL thickening correlates with disease severity and progression or whether there are any specific genotype–OCT correlations. The molecular genetic basis of inherited ataxia and spastic paraplegia syndromes is highly heterogeneous—a situation that poses a number of diagnostic challenges in neurology clinics. In Friedreich's ataxia, which is the most common form of autosomal recessive ataxia, variable reduction in RNFL thickness has been reported among visually asymptomatic patients.10 In a recent OCT study, we found a normal RNFL profile among patients harbouring SPG4 mutations, which account for ∼40% of all autosomal-dominant cases of hereditary spastic paraplegia.11 A dilated fundus examination and OCT imaging should therefore be considered in patients with unexplained multisystem neurological disease. When present, retinal striations and RNFL thickening raise the distinct possibility of ARSACS, and SACS genetic screening should be considered.
  10 in total

1.  ARSACS, a spastic ataxia common in northeastern Québec, is caused by mutations in a new gene encoding an 11.5-kb ORF.

Authors:  J C Engert; P Bérubé; J Mercier; C Doré; P Lepage; B Ge; J P Bouchard; J Mathieu; S B Melançon; M Schalling; E S Lander; K Morgan; T J Hudson; A Richter
Journal:  Nat Genet       Date:  2000-02       Impact factor: 38.330

2.  Mitochondrial dysfunction and Purkinje cell loss in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS).

Authors:  Martine Girard; Roxanne Larivière; David A Parfitt; Emily C Deane; Rebecca Gaudet; Nadya Nossova; Francois Blondeau; George Prenosil; Esmeralda G M Vermeulen; Michael R Duchen; Andrea Richter; Eric A Shoubridge; Kalle Gehring; R Anne McKinney; Bernard Brais; J Paul Chapple; Peter S McPherson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

3.  Thickening of peripapillar retinal fibers for the diagnosis of autosomal recessive spastic ataxia of Charlevoix-Saguenay.

Authors:  Jeremy Desserre; David Devos; Bruno Georges Sautière; Philippe Debruyne; Filippo M Santorelli; Isabelle Vuillaume; Sabine Defoort-Dhellemmes
Journal:  Cerebellum       Date:  2011-12       Impact factor: 3.847

4.  Sacsinopathies: sacsin-related ataxia.

Authors:  Yoshihisa Takiyama
Journal:  Cerebellum       Date:  2007-02-28       Impact factor: 3.847

5.  Visual system involvement in patients with Friedreich's ataxia.

Authors:  Filippo Fortuna; Piero Barboni; Rocco Liguori; Maria Lucia Valentino; Giacomo Savini; Cinzia Gellera; Caterina Mariotti; Giovanni Rizzo; Caterina Tonon; David Manners; Raffaele Lodi; Alfredo A Sadun; Valerio Carelli
Journal:  Brain       Date:  2008-10-18       Impact factor: 13.501

6.  Prominent sensorimotor neuropathy due to SACS mutations revealed by whole-exome sequencing.

Authors:  Angela Pyle; Helen Griffin; Patrick Yu-Wai-Man; Jennifer Duff; Gail Eglon; Stuart Pickering-Brown; Mauro Santibanez-Korev; Rita Horvath; Patrick F Chinnery
Journal:  Arch Neurol       Date:  2012-10

7.  The neurological and ophthalmological manifestations of SPG4-related hereditary spastic paraplegia.

Authors:  Grant Guthrie; Gerald Pfeffer; Maura Bailie; Karen Bradshaw; Andrew C Browning; Rita Horvath; Patrick F Chinnery; Patrick Yu-Wai-Man
Journal:  J Neurol       Date:  2012-12-13       Impact factor: 4.849

8.  Retinal nerve fiber hypertrophy in ataxia of Charlevoix-Saguenay patients.

Authors:  Luis E Pablo; Elena Garcia-Martin; Jose Gazulla; Jose M Larrosa; Antonio Ferreras; Filippo M Santorelli; Isabel Benavente; Ana Vela; Miguel A Marin
Journal:  Mol Vis       Date:  2011-07-13       Impact factor: 2.367

9.  Late-onset sacsinopathy diagnosed by exome sequencing and comparative genomic hybridization.

Authors:  Angela Pyle; Helen Griffin; Jennifer Duff; Shona Bennett; Simon Zwolinski; Tania Smertenko; Patrick Yu-Wai Man; Mauro Santibanez-Koref; Rita Horvath; Patrick F Chinnery
Journal:  J Neurogenet       Date:  2013-11-04       Impact factor: 1.250

10.  Retinal nerve fibre layer thickness in ARSACS: myelination or hypertrophy?

Authors:  Elena Garcia-Martin; Luis E Pablo; Jose Gazulla; Vicente Polo; Antonio Ferreras; Jose M Larrosa
Journal:  Br J Ophthalmol       Date:  2012-10-17       Impact factor: 4.638

  10 in total
  6 in total

1.  Absent Foveal Avascular Zone in Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay.

Authors:  Vivian Paraskevi Douglas; Konstantinos A A Douglas; John B Miller; Eric D Gaier
Journal:  J Neuroophthalmol       Date:  2021-06-01       Impact factor: 3.042

2.  Novel compound heterozygous mutation in SACS gene leads to a milder autosomal recessive spastic ataxia of Charlevoix-Saguenay, ARSACS, in a Finnish family.

Authors:  Johanna Palmio; Mikko Kärppä; Peter Baumann; Sini Penttilä; Jukka Moilanen; Bjarne Udd
Journal:  Clin Case Rep       Date:  2016-10-26

3.  Genetic heterogeneity of motor neuropathies.

Authors:  Boglarka Bansagi; Helen Griffin; Roger G Whittaker; Thalia Antoniadi; Teresinha Evangelista; James Miller; Mark Greenslade; Natalie Forester; Jennifer Duff; Anna Bradshaw; Stephanie Kleinle; Veronika Boczonadi; Hannah Steele; Venkateswaran Ramesh; Edit Franko; Angela Pyle; Hanns Lochmüller; Patrick F Chinnery; Rita Horvath
Journal:  Neurology       Date:  2017-03-01       Impact factor: 9.910

4.  A Chromosomal Deletion and New Frameshift Mutation Cause ARSACS in an African-American.

Authors:  Sean C Dougherty; Amy Harper; Hind Al Saif; Gregory Vorona; Scott R Haines
Journal:  Front Neurol       Date:  2018-11-15       Impact factor: 4.003

Review 5.  Documenting manifestations and impacts of autosomal recessive spastic ataxia of Charlevoix-Saguenay to develop patient-reported outcome.

Authors:  Marjolaine Tremblay; Laura Girard-Côté; Bernard Brais; Cynthia Gagnon
Journal:  Orphanet J Rare Dis       Date:  2022-10-01       Impact factor: 4.303

6.  Inner Retinal Dysfunction in the Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay.

Authors:  François-Xavier Borruat; Graham E Holder; Fion Bremner
Journal:  Front Neurol       Date:  2017-10-12       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.